All In Biotech

Drug Trial Radar · NCT07944144

A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid Tumors

An Open-label Phase I/II, Dose Escalation, Dose Optimization, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity, and Antitumor Activity of IPN60350 as Monotherapy or in Combination With Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 205 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

205

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Jun 28, 2030

Study completion Sep 30, 2030

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety of a new medicine called IPN60350 and how the body responds to it. Researchers will also look for early signs of antitumor activity in adults with locally advanced or metastatic solid tumors. All participants in this study will receive IPN60350, either alone or in combination with other anticancer therapies. The study has two parts. * Phase Ia (dose escalation) will test IPN60350 at different dose levels to learn which doses are safe and can be given in future parts of the study. * Phase Ib (dose optimization and expansion) will test one or more selected dose levels in a larger number of participants. This will help researchers better understand the safety of IPN60350 and whether it shows early signs of antitumor activity in different tumor types. Each part will consist of the following periods: * A screening period (up to 28 days) to assess whether the participant can take part, requiring at least 1 visit to the study center. * A treatment period where IPN60350 is administered in repeating treatment cycles. The study includes health assessments, blood tests, tissue samples (biopsies), and imaging scans to help researchers better understand the safety of IPN60350 and its potential effects on tumors.

Conditions

  • Neoplasms
  • Neoplasm Metastasis
  • Neoplastic Processes
  • Pathologic Processes

Interventions

  • IPN60350Biological

    IPN60350 will be administered at the assigned dose level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to Day 21 following study drug administration
  2. Phase Ia and Ib: Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)
  3. Phase Ib: Objective Response Rate (ORR)Time frame: From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
  4. Phase Ib: Percentage of Participants With Dose Interruptions and Permanent Treatment DiscontinuationsTime frame: From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.